Maryam Lustberg, Director Breast Center/Chief Breast Oncology at Yale University School of Medicine, shared Personalis, Inc.’s post on LinkedIn:
“Proud of this translational collaboration with Personalis, Inc. and the Translational Breast Cancer Consortium(TBCRC) and Yale School of Medicine Menarini Stemline
The study will help advance our understanding of late recurrences in hormone receptor positive breast cancer using blood based biomarkers and new targeted therapy.
Congratulations to study chair, my brilliant mentee Dr. Mariya Rozenblit and the entire study team.”
Quoting Personalis, Inc.‘s post:
“ICYMI: Last week we announced a collaboration with a leading breast cancer team from Yale Cancer Center for the CATE clinical trial, a novel ctDNA-guided study aimed at improving outcomes in patients with breast cancer.
The prospective, multi-center trial, sponsored by the Translational Breast Cancer Research Consortium (TBCRC) and led by Dr. Mariya Rozenblit and Dr. Maryam Lustberg at Yale Cancer Center, will investigate whether earlier, ultrasensitive ctDNA-guided intervention can prevent metastatic relapse and improve outcomes for patients with HR+/HER2- breast cancer.
HR+/HER2- breast cancer, which accounts for over 70% of all cases, poses a significant challenge due to the risk of late recurrence.
The CATE trial utilizes the NeXT Personal test to identify the earliest molecular signs of recurrence, ahead of standard imaging. Patients who test positive will be preemptively treated with elacestrant, a next-generation therapy, with the goal of eliminating cancer before it becomes metastatic.
Learn more from the press release.
See what’s being said in the news about this pivotal trial.”
More insights from Maryam Lustberg.